跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
新可来 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Mepolizumab Injection
Approved
生物制品
Mepolizumab Injection
GLAXOSMITHKLINE TRADING SERVICES LIMITED
🇨🇳 National Medical Products Administration
Approval Date
Dec 25, 2024
Approval ID
8BYtsNkuP9l
Company
GLAXOSMITHKLINE TRADING SERVICES LIMITED
Type
生物制品
Approval Details
Approval Id
8BYtsNkuP9l
Approval Number
国药准字SJ20210030
Generic Name
美泊利珠单抗注射液
Generic Name En
Mepolizumab Injection
Trade Name
新可来
Drug Type
生物制品
Dosage Form
注射剂
Strength
100mg (1ml)/支(单剂量预充式安全注射器)
Reg Date
2024-12-25
Expired Date
2026-11-16
Company Name
GLAXOSMITHKLINE TRADING SERVICES LIMITED
Production Company Name
Glaxo Operations UK Ltd.
Company Detail Path
/organization/glaxosmithkline-trading-services-limited
Production Company Detail Path
/organization/glaxo-operations-uk-ltd
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 25, 2024
Approval ID
8BYtsNkuP9l
Type
生物制品
Back to NMPA Approvals